SRCAP and neoplasm: The remaining tumor fraction comprises a heterogenous group characterized by genetic alterations leading to overexpression of HMGA1/HMGA2, inactivation of the SRCAP histone loading complex, or biallelic loss of fumarate hydratase [9, 10].